Stock Ratings / Health Care / LRMR / financials

BCYC (20) GLSI (31) AMRN (32) ABEO (23) ⌘ Pro Terminal →

Larimar Therapeutics Inc. (LRMR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.47 -7.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.43

Larimar Therapeutics Inc. (LRMR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $256.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LRMR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LRMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Larimar Therapeutics Inc. (NASDAQ: LRMR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.47 (-7.49% 1D, market cap $256.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LRMR ranks #629 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LRMR compare to BCYC and GLSI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LRMR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, LRMR leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LRMR?

▼

Per LRMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374690), Larimar Therapeutics Inc. generated $0 in revenue, -$165.7M in net income, and -$113.3M in free cash flow against $145.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.43 (-1.54%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LRMR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY LRMR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.16+13% Next Q

Q2 (-2Q)

Grade E$2.44-2% Next Q

Q3 (-1Q)

Grade E$2.39+3.3% Next Q

Current

Grade E$2.47-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LRMR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LRMR currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.15) and Max Pain ($2.59) forces dealer call-delta covering toward $6.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LRMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LRMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LRMR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-4.3%	-$165.7M	-$113.3M	-45%
FY 2024	$4.00B	52%	-2.3%	-$80.6M	-$71.3M	-45%
FY 2023	$4.00B	52%	-1%	-$36.9M	-$33.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LRMR)

✓Walkthrough of LRMR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LRMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.47%📐 HORIZONTAL RANGE

2026-11-03O $2.67H $2.67L $2.47C $2.47VOL 781.3K

RES: $4.63SUP: $1.76SMA50: $3.15SMA200: $3.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LRMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LRMR Butterfly Map → + Track LRMR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LRMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LRMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LRMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LRMR)

Health Care Rank #629 of 1016 ⚔️ BCYC vs LRMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LRMR vs. BCYC, GLSI, AMRN, ABEO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Larimar Therapeutics Inc. (LRMR) ranks #629 by composite RQD confidence (34/100, grade E) and #535 by equity capitalization ($256.6M). Within this direct 5-issuer industry benchmark cohort, LRMR leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. LRMR currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LRMR ACTIVE Larimar Therapeutics Inc.	E	34/100	—	—	-35.0%	-7.49%	$256.6M	Benchmark Subject
BCYC Bicycle Therapeutics plc	E	20/100	—	—	-35.0%	-4.19%	$256.5M	/bcyc-vs-lrmr →
GLSI Greenwich LifeSciences Inc.	E	31/100	—	—	-35.0%	-8.37%	$255.5M	/glsi-vs-lrmr →
AMRN Amarin Corporation plc	E	32/100	—	56.6%	-12.2%	-4.91%	$249.9M	/amrn-vs-lrmr →
ABEO Abeona Therapeutics Inc.	E	23/100	—	73.7%	-35.0%	-4.61%	$248.8M	/abeo-vs-lrmr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001374690

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Larimar Therapeutics Inc. (LRMR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$165.7M, operating cash flow of -$113.2M, and free cash flow of -$113.3M (-59.0% YoY). On the balance sheet, LRMR closed FY2025 with $145.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$165.7M	-$113.2M	-$113.3M	$145.8M	—
FY2024 (FY)	2024-12-31	$0	-$80.6M	-$70.8M	-$71.3M	$200.2M	—
FY2023 (FY)	2023-12-31	$0	-$36.9M	-$33.5M	-$33.5M	—	—

3. LRMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LRMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LRMR compare to BCYC and GLSI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LRMR?

Where is LRMR trading relative to its 50-day, 200-day, and 52-week technical levels?

LRMR last traded at $2.47 (-7.49% on volume of 781,292 shares), positioning the stock -21.59% below its 50-day simple moving average ($3.15) and -35.00% below its 200-day simple moving average ($3.80). Across its 52-week range of $1.91 to $6.42, LRMR sits at the 12.4% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.16 to $2.78).

LRMR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Larimar Therapeutics Inc. (LRMR)?

In FY 2025 (10-K), LRMR converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: LRMR RQD Cockpit LRMR 12M Forecast LRMR Earnings & Move LRMR Dividends & DRIP LRMR Insiders & 13F LRMR Whale Options LRMR Profit Sankey LRMR News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LRMR — Larimar Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:39:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LRMR scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental Cash Engine (8 / 20): Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow, so value depends on future outcomes not yet visible in reported results.
Whale 13F Flow (5 / 20): The rating cites institutional accumulation and options positioning as weak in its scoring. Investors should note that institutional support appears limited relative to the other pillars.
Insider Conviction (5 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow scored low. This suggests limited insider-side conviction signals in the data.
Macro Regime Fit (8 / 20): Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is scored weakly. The stock moves in line with the broad market by beta, but the rating treats its fit to the current macro regime as unfavorable.
Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These figures point to a financially stressed profile on the Piotroski measure, with leverage moderate by the reported ratio.

Taken together, the rating frames LRMR as a high-risk, cash-consuming name where the upside case depends on catalysts rather than current fundamentals. The tradeoff a prospective investor faces is an apparent low entry price ($2.67) against negative returns and weak flow scores.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-172.5M	$-165.7M	N/A	$-113.3M	$85.4M	N/A
FY 2024	$0.0M	$-90.9M	$-80.6M	N/A	$-71.3M	$33.2M	N/A
FY 2023	$0.0M	$-41.8M	$-36.9M	N/A	$-33.5M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M in each period, and operating losses widened from $-41.8M (FY 2023) to $-172.5M (FY 2025). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the SEC financials, cash rose to $85.4M in FY 2025, while FCF was $-113.3M, and debt is N/A in the source.

Open Questions

What are LRMR's products, clinical pipeline stage, and commercial revenue path, given reported revenue is $0.0M across all periods?
How long does current cash of $85.4M fund operating losses of $-172.5M at the FY 2025 burn rate, and what financing is planned?
What is the basis and source of the $14.89 price target cited in the news wire, and is it corroborated by analyst coverage?
Why is debt reported as N/A, and how does the Debt/Equity of 0.5 reconcile with the reported figures?
What specific clinical, regulatory, or partnering catalysts are scheduled, and when?

LRMR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Larimar Therapeutics Inc. (LRMR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LRMR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 17h ago

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Yahoo Finance UK report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 20h ago

Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside

TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 23h ago

Larimar Therapeutics Stock Price Forecast. Should You Buy LRMR?

StockInvest.us report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Larimar Therapeutics (NasdaqGM:LRMR) Aktienprognose & Analystenschätzungen

Simply Wall St report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Larimar Therapeutics, Inc. Estimates – NASDAQ:LRMR

TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

MarketBeat report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 1d ago

Protara Therapeutics, Inc. (TARA) Seasonal returns chart

Yahoo Finance Australia report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

LRMR Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LRMR Bull vs. Bear Conversation Board — What's Your Call at $2.47?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LRMR 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.35 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LRMR (D- • RQD 36/100) a Buy at $2.67?

Welcome to the LRMR (Larimar Therapeutics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.06 (-22.8%)

Spot @ $2.67

Pump the brakes on LRMR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LRMR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Larimar Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.36 (+25.8%)

Spot @ $2.67

LRMR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LRMR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.67 (52-wk range $1.91 - $6.42), any beat on forward guidance forces shorts and underweight funds to chase.